Physician profile
Michael B Kerner
NPI 1982693990
$4,169.98
in general payments reported to CMS, 2019-2025
22 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $446 · 2021: $518 · 2022: $511 · 2023: $640 · 2024: $828 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625 · Education: $16.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.67 |
| Education | $16.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,154.15 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $470.22 | 2019-2024 | Xifaxan |
| Pfizer INC. | $331.82 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $285.81 | 2019-2023 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $245.13 | 2021-2023 | |
| Janssen Biotech, INC. | $174.22 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $77.96 | 2019-2021 | |
| Celgene Corporation | $57.80 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $56.09 | 2019 | |
| Aimmune Therapeutics, INC. | $50.63 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $43.73 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $42.49 | 2019-2020 | |
| Medtronic, INC. | $40.37 | 2024 | Gi Genius |
| Jazz Pharmaceuticals INC. | $19.30 | 2021 | |
| Genzyme Corporation | $16.54 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $16.33 | 2024 | Zymfentra |
| Amgen INC. | $14.99 | 2020 | |
| Ironwood Pharmaceuticals, INC | $14.98 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.98 | 2020 | |
| Allergan, INC. | $14.53 | 2019 | |
| Lilly USA, LLC | $14.52 | 2023 | |
| Vivus LLC | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.